Comparative risks of potential adverse events following COVID-19 mRNA vaccination among older adults

About The Study: In this study of 6.3 million older U.S. adults, the mRNA-1273 (Moderna) vaccine was associated with a slightly lower risk of several adverse events compared with BNT162b2 (Pfizer-BioNTech), possibly due to greater protection against COVID-19. Future research should seek to formally disentangle differences in vaccine safety and effectiveness and consider the role of frailty in assessments of COVID-19 vaccine performance.

Authors: Daniel A. Harris, Ph.D., of the Brown University School of Public Health in Providence, Rhode Island, is the corresponding author. 

 To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2023.26852)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.26852?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=080223

END